The clinical isolation rate of multidrug-resistant or pan-resistant Acinetobacter baumannii (A.
baumannii) is increasing, resulting that optional antibiotics are very limited in clinical …

Increasing antibiotic resistance of Acinetobacter baumannii highlights the urgent need to
develop an effective vaccine to combat it. Despite all efforts, no approved vaccine against …

Multi-epitope polypeptide vaccines, a fusion protein, often have a string-of-beads system
composed of various specific peptide epitopes, potential adjuvants, and linkers. When …

As one of the most influential and troublesome human pathogens, Acinetobacter baumannii
(A. baumannii) has emerged with many multidrug-resistant strains. After collecting 33 …

Antibiotic resistance (AR) is the result of microbes' natural evolution to withstand the action
of antibiotics used against them. AR is rising to a high level across the globe, and novel …

In the last decade, Multi-drug resistance (MDR)-associated infections of Acinetobacter
baumannii have grown worldwide. A cost-effective preventative strategy against this …

Acinetobacter baumannii (Ab) is a global emerging bacterium causing nosocomial infections
such as pneumonia, meningitis, bacteremia and soft tissue infections especially in intensive …

Outer membrane protein A (OmpA) is the most promising vaccine candidate against one of
the most successful nosocomial pathogens, A. baumannii. Despite advantages of the …

Acinetobacter baumannii is a Gram-negative, opportunistic pathogen that causes
nosocomial infection with a high mortality rate in immunocompromised individuals. With the …

Infections caused by multi-drug resistance Acinetobacter baumannii are increasing
worldwide. Discovery of the vaccine against this bacterium as a cost-effective and preventive …